Carregant...
POD24 in MZL: a means to an end or an end point in itself?
In this issue of Blood, Luminari et al demonstrate that patients with marginal zone lymphoma (MZL) who experience early progression (progression of disease at 24 months [POD24]) have poor survival.(1) Overall survival after POD24 was 53% at 3 years, a stark contrast to the 95% 5-year survival rate f...
Guardat en:
| Publicat a: | Blood |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6729009/ https://ncbi.nlm.nih.gov/pubmed/31488454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019002305 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|